Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0111 Transporter Info
Gene Name	SLC16A7
Transporter Name	Monocarboxylate transporter 2
Gene ID	9194
UniProt ID	O60669

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Estradiol co-treated with Norethindrone Acetate results in decreased expression of SLC16A7 mRNA			[33]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Estradiol co-treated with Tetrachlorodibenzodioxin results in increased expression of SLC16A7 mRNA			[5]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Estradiol co-treated with TGFB1 protein results in decreased expression of SLC16A7 mRNA			[34]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cisplatin co-treated with jinfukang results in decreased expression of SLC16A7 mRNA			[8]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Tretinoin affects the expression of SLC16A7 mRNA			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Tretinoin results in increased expression of SLC16A7 mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Valproic Acid affects the expression of SLC16A7 mRNA			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Valproic Acid results in decreased methylation of SLC16A7 gene			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
3-iodothyronamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC16A7 mRNA affects the uptake of 3-iodothyronamine			[21]
Regulation Mechanism				Transcription Factor Info
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SLC16A7 mRNA			[23]
Regulation Mechanism				Transcription Factor Info
abrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	abrine results in decreased expression of SLC16A7 mRNA			[24]
Regulation Mechanism				Transcription Factor Info
Acrolein	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
alpha-pinene	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
AR C155858	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	AR C155858 results in decreased activity of SLC16A7 protein			[28]
Regulation Mechanism				Transcription Factor Info
aristolochic acid I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	aristolochic acid I results in decreased expression of SLC16A7 mRNA			[29]
Regulation Mechanism				Transcription Factor Info
Benzo(a)pyrene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC16A7 intron			[27]
Regulation Mechanism				Transcription Factor Info
bisphenol A	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A results in increased expression of SLC16A7 protein			[18]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	bisphenol A results in increased methylation of SLC16A7 gene			[31]
Regulation Mechanism				Transcription Factor Info
bisphenol AF	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol AF results in increased expression of SLC16A7 protein			[18]
Regulation Mechanism				Transcription Factor Info
bisphenol B	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol B results in increased expression of SLC16A7 protein			[18]
Regulation Mechanism				Transcription Factor Info
bisphenol F	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol F results in increased expression of SLC16A7 protein			[18]
Regulation Mechanism				Transcription Factor Info
bisphenol S	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol S results in increased expression of SLC16A7 protein			[18]
Regulation Mechanism				Transcription Factor Info
coumarin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	coumarin results in increased phosphorylation of SLC16A7 protein			[32]
Regulation Mechanism				Transcription Factor Info
dorsomorphin	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
gallium arsenide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	gallium arsenide results in decreased expression of SLC16A7 mRNA			[35]
Regulation Mechanism				Transcription Factor Info
geldanamycin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	geldanamycin results in increased expression of SLC16A7 mRNA			[15]
Regulation Mechanism				Transcription Factor Info
licochalcone B	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	licochalcone B results in decreased expression of SLC16A7 mRNA			[36]
Regulation Mechanism				Transcription Factor Info
methacrylaldehyde	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
methylselenic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	methylselenic acid results in increased expression of SLC16A7 mRNA			[37]
Regulation Mechanism				Transcription Factor Info
Norethindrone Acetate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol co-treated with Norethindrone Acetate results in decreased expression of SLC16A7 mRNA			[33]
Regulation Mechanism				Transcription Factor Info
Ozone	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Volatile Organic Compounds co-treated with Ozone results in decreased expression of SLC16A7 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
p-Chloromercuribenzoic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	p-Chloromercuribenzoic Acid results in decreased expression of SLC16A7 mRNA			[14]
Regulation Mechanism				Transcription Factor Info
Silicon Dioxide	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Silicon Dioxide analog results in decreased expression of SLC16A7 mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Silicon Dioxide results in decreased expression of SLC16A7 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in decreased expression of SLC16A7 mRNA			[40]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	sodium arsenite results in increased abundance of Arsenic which results in decreased expression of SLC16A7 mRNA			[30]
Regulation Mechanism				Transcription Factor Info
tamibarotene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tamibarotene affects the expression of SLC16A7 mRNA			[2]
Regulation Mechanism				Transcription Factor Info
testosterone enanthate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	testosterone enanthate affects the expression of SLC16A7 mRNA			[3]
Regulation Mechanism				Transcription Factor Info
Tetrachlorodibenzodioxin	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol co-treated with Tetrachlorodibenzodioxin results in increased expression of SLC16A7 mRNA			[5]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Tetrachlorodibenzodioxin affects the expression of SLC16A7 mRNA			[41]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Tetrachlorodibenzodioxin results in increased expression of SLC16A7 mRNA			[5]
Regulation Mechanism				Transcription Factor Info
Thiram	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Thiram results in decreased expression of SLC16A7 mRNA			[40]
Regulation Mechanism				Transcription Factor Info
trichostatin A	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC16A7 mRNA			[22]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	trichostatin A results in increased expression of SLC16A7 mRNA			[43]
Regulation Mechanism				Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC16A7 mRNA			[44]
Regulation Mechanism				Transcription Factor Info
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 results in increased methylation of SLC16A7 intron			[27]
Regulation Mechanism				Transcription Factor Info
Carcinogen
Arsenic	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in decreased expression of SLC16A7 mRNA			[30]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Testosterone enanthate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Testosterone enanthate affects the expression of SLC16A7			[3]
Copper Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Copper Sulfate inhibits the expression of SLC16A7			[4]
Estradiol	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol increases the expression of SLC16A7			[5]
Isotretinoin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Isotretinoin inhibits the expression of SLC16A7			[6]
Progesterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Progesterone inhibits the expression of SLC16A7			[7]
Cisplatin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cisplatin inhibits the expression of SLC16A7			[8]
Doxorubicin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Doxorubicin inhibits the expression of SLC16A7			[9]
Tretinoin	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tretinoin inhibits the expression of SLC16A7			[10]
Acetaminophen	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the expression of SLC16A7			[11]
DT Modulation2	Acetaminophen results in increased expression of SLC16A7 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
Valproic Acid	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic Acid increases the expression of SLC16A7			[12]
Testosterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Testosterone inhibits the activity of SLC16A7			[13]
Drug in Phase 2/3 Trial
AM-80	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	AM-80 affects the expression of SLC16A7			[2]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol A increases the expression of SLC16A7			[18]
Bisphenol B	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol B increases the expression of SLC16A7			[18]
Drug in Phase 1 Trial
Geldanamycin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Geldanamycin increases the expression of SLC16A7			[15]
Trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Trichostatin A increases the expression of SLC16A7			[15]
Investigative Drug
AR-C155858	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	AR-C155858 inhibits the transportation of Ketone bodies and L-lactate by SLC16A7 (IC50 = 1 microM)			[1]
Affected Drug/Substrate	Ketone bodies and L-lactate	Modulation Type	Inhibition
Cell System	Breast cancer cell lines-MCT2
Phenylmercuric Acetate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenylmercuric Acetate increases the expression of SLC16A7			[14]
Natural Product
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution inhibits the expression of SLC16A7			[17]
Traditional Medicine
Jinfukang	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Jinfukang inhibits the expression of SLC16A7			[8]
Dietary Constituent
Ketogenic diet	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ketogenic diet induces the activity of SLC16A7			[20]
Environmental toxicant
Bisphenol F	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol F increases the expression of SLC16A7			[18]
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Polychlorinated dibenzodioxin increases the expression of SLC16A7			[19]
Acute Toxic Substance
Formaldehyde	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Formaldehyde inhibits the expression of SLC16A7			[16]

References
1	Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014 Nov 30;5(22):11029-37.
2	Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
3	Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802.
4	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
5	Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
6	Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
7	Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
8	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
9	Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
10	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
11	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
12	Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
13	Developmental and hormonal regulation of the monocarboxylate transporter 2 (MCT2) expression in the mouse germ cells. Biol Reprod. 2003 Sep;69(3):1069-78.
14	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
15	Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
16	Cystathionine metabolic enzymes play a role in the inflammation resolution of human keratinocytes in response to sub-cytotoxic formaldehyde exposure. Toxicol Appl Pharmacol. 2016 Nov 1;310:185-194.
17	Multi-omics analysis: Repeated exposure of a 3D bronchial tissue culture to whole-cigarette smoke. Toxicol In Vitro. 2019 Feb;54:251-262.
18	Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730.
19	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
20	Monocarboxylate transporters in temporal lobe epilepsy: roles of lactate and ketogenic diet. Brain Struct Funct. 2015 Jan;220(1):1-12.
21	Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.
22	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
23	Temporal gene expression changes induced by a low concentration of benzo[a]pyrene diol epoxide in a normal human cell line. Mutat Res. 2010;684(1-2):74-80.
24	Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
25	Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
26	Post-transcriptional air pollution oxidation to the cholesterol biosynthesis pathway promotes pulmonary stress phenotypes. Commun Biol. 2020;3(1):392.
27	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
28	Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation. Oncotarget. 2015;6(32):33568-86.
29	Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
30	Using transcriptomic signatures to elucidate individual and mixture effects of inorganic arsenic and manganese in human placental trophoblast HTR-8/SVneo cells. Toxicol Sci. 2025;203(2):216-226.
31	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
32	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022;449:116110.
33	A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thromb Res. 2012;130(1):45-51.
34	Transforming growth factor beta1 targets estrogen receptor signaling in bronchial epithelial cells. Respir Res. 2018 Aug 30;19(1):160.
35	RNA Sequencing Analyses Reveal the Potential Mechanism of Pulmonary Injury Induced by Gallium Arsenide Particles in Human Bronchial Epithelioid Cells. Sci Rep. 2020;10(1):8685.
36	Integrated miRNA and mRNA omics reveal the anti-cancerous mechanism of Licochalcone B on Human Hepatoma Cell HepG2. Food Chem Toxicol. 2021;150:112096.
37	Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics Proteomics. 2005;2(2):97-114.
38	High-throughput, quantitative assessment of the effects of low-dose silica nanoparticles on lung cells: grasping complex toxicity with a great depth of field. BMC Genomics. 2015;16(1):315.
39	Differences in gene expression and cytokine production by crystalline vs. amorphous silica in human lung epithelial cells. Part Fibre Toxicol. 2012;9(1):6.
40	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
41	Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci. 2012 May;127(1):199-215.
42	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
43	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
44	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
45	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
46	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence